Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?
Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?
You may also be interested in...
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.